Back to top

gene-editing: Archive

Zacks Equity Research

Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

RHHBYNegative Net Change SRPTNegative Net Change ARWRNegative Net Change

Zacks Equity Research

CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.

VRTXNegative Net Change CRSPNegative Net Change GMABPositive Net Change IMCRNegative Net Change

Ekta Bagri

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

ILMNPositive Net Change BEAMPositive Net Change EDITNegative Net Change NTLAPositive Net Change PRMENegative Net Change CRSPNegative Net Change